AI assistant
Sending…
Ernexa Therapeutics Inc. — Director's Dealing 2021
Jun 22, 2021
35259_dirs_2021-06-22_e2b8cd03-9101-467a-b42f-66690ee548d6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Brooklyn ImmunoTherapeutics, Inc. (BTX)
CIK: 0000748592
Period of Report: 2021-06-21
Reporting Person: Gurrola Sandra M (N/A)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 8203 | Direct |
More from Ernexa Therapeutics Inc.
Major Shareholding Notification
2026
May 14
Annual Report
2026
May 11
Proxy Solicitation & Information Statement
2026
May 11
Proxy Solicitation & Information Statement
2026
May 11
Interim / Quarterly Report
2026
May 11
Share Issue/Capital Change
2026
May 4
Regulatory Filings
2026
Apr 13
Regulatory Filings
2026
Apr 1
Regulatory Filings
2026
Mar 31
Capital/Financing Update
2026
Mar 24